

---

**PDVAC virtual session on “Preferred Product Characteristics and Target Product Profiles”  
22 April 2020**

<b>PDVAC COMMITTEE MEMBERS</b>
--------------------------------

**Klaus Cichutek** (*apologies*)

Paul-Ehrlich-Institute (PEI)  
Langen, Germany

[klaus.cichutek@pei.de](mailto:klaus.cichutek@pei.de)

**Sinead Delany-Moretlwe**

University of Witwatersrand (Wits)  
Johannesburg, South Africa

[sdelany@wrhi.ac.za](mailto:sdelany@wrhi.ac.za)

**Bernard Fritzell**

Independent  
Bordeaux, France

[bernardfritzell@hotmail.fr](mailto:bernardfritzell@hotmail.fr)

**Barney Graham**

NIAID, Vaccine Research Center  
Bethesda, USA

[bgraham@mail.nih.gov](mailto:bgraham@mail.nih.gov)

**Gagandeep Kang**

Translational Health Science and Technology  
Institute (THSTI)  
Faridabad, India

[gkang@thsti.res.in](mailto:gkang@thsti.res.in)

**Ruth Karron**

Johns Hopkins Bloomberg School of Public Health  
(JHSPH)  
Baltimore, USA

[rkarron@jhsph.edu](mailto:rkarron@jhsph.edu)

**David Kaslow (CHAIR)**

PATH  
Seattle, USA

[dkaslow@path.org](mailto:dkaslow@path.org)

**Jerome Kim**

International Vaccine Institute (IVI)  
Seoul, Korea

[Jerome.Kim@ivi.int](mailto:Jerome.Kim@ivi.int)

**Claudio Lanata**

Instituto de Investigación Nutricional  
Lima, Peru

[clanata@iin.sld.pe](mailto:clanata@iin.sld.pe)

**Shabir Madhi**

Witwatersrand University  
Johannesburg, South Africa

[madhis@rmpru.co.za](mailto:madhis@rmpru.co.za)

**Beno Y. Nyam**

National Agency for Food and Drug Administration and  
Control  
Lagos, Nigeria

[beno.y@nafdac.gov.ng](mailto:beno.y@nafdac.gov.ng)

**Mark Papania**

Centers for Disease Control and Prevention  
Atlanta, USA

[myp7@cdc.gov](mailto:myp7@cdc.gov)

**Yiming Shao**

Chinese Center for Disease Control and Prevention  
(CDC)  
Beijing, China

[yshao@bjmu.edu.cn](mailto:yshao@bjmu.edu.cn)

**Marian W. Wentworth**

Management Sciences for Health (MSH)  
Medford, USA

[mwentworth@msh.org](mailto:mwentworth@msh.org)

**NON- MEMBER PARTICIPANTS****Isabelle Bekerredjian-Ding**

Paul-Ehrlich-Institute (PEI)  
Langen, Germany

[Isabelle.Bekerredjian-Ding@pei.de](mailto:Isabelle.Bekerredjian-Ding@pei.de)

**Alejandro Cravioto**

University of Mexico  
Puerto Vallarta, Mexico

[dracravioto@hotmail.com](mailto:dracravioto@hotmail.com)

**WHO HQ SECRETARIAT**

**Adwoa Benstsi-Enchill**, Medical Officer, Vaccine Product & Delivery Research, IVB

**Daniel Feikin**, Consultant, Vaccine Product & Delivery Research, IVB

**Martin Friede**, Unit Head, Vaccine Product & Delivery Research, IVB

**Birgitte Giersing**, Team Lead (a.i.), Vaccine Prioritization and Platforms, Vaccine Product & Delivery Research, IVB

**Mateusz Hasso-Agopsowicz**, Consultant, Vaccine Product & Delivery Research, IVB

**Erin Sparrow**, Technical Officer, Vaccine Prioritization and Platforms, Vaccine Product & Delivery Research, IVB

**Johan Vekemans**, Medical Officer, Vaccine Product & Delivery Research, IVB